Efficacy of Topical Finasteride 0.5% vs 17α-Estradiol 0.05% in the Treatment of Postmenopausal Female Pattern Hair Loss: A Retrospective, Single-Blind Study of 119 Patients.
17α-estriadol
female pattern hair loss
minoxidil
topical finasteride
Journal
Dermatology practical & conceptual
ISSN: 2160-9381
Titre abrégé: Dermatol Pract Concept
Pays: Austria
ID NLM: 101585990
Informations de publication
Date de publication:
2020
2020
Historique:
accepted:
03
11
2019
entrez:
5
5
2020
pubmed:
5
5
2020
medline:
5
5
2020
Statut:
epublish
Résumé
Female pattern hair loss (FPHL) is a common form of scalp hair loss that occurs in 38% of females. Currently, minoxidil solution is the only therapy approved by the US Food and Drug Administration, but many other treatments are used, including cyproterone acetate, spironolactone, topical 17α-estradiol, and prostaglandin analogs. Systemic finasteride has been considered a treatment option in women even though its teratogenic effects tend to limit its prescription. Recently, topical finasteride has been evaluated to limit the side effect profile of the drug. The objective of the present study is to compare retrospectively the efficacy of topical 0.05% 17α-estradiol solution and a 0.5% finasteride lotion in the treatment of FPHL. We enrolled 119 postmenopausal female patients. The first group comprised 69 women treated with finasteride 0.5% and minoxidil 2%. The second group included 50 women treated with 17α-estradiol 0.05% and minoxidil 2%. At baseline and at 6- and 12- to 18-month follow-up, global photographs were systematically taken. Three operators blind to the prescribed treatment evaluated photographs using a 7-point scale. One-way analysis of variance and unpaired Student t tests were performed to analyze 7-point scale scores. The improvement was statistically significant from 6 months to 12-18 months, both for finasteride (P < 0.005) and 17α-estradiol (P < 0.05). The efficacy of topical finasteride was significantly greater than that of 17α-estradiol solution, both at the 6-month (P < 0.05) and at the 12- to 18-month follow-up (P < 0.005). In general, the highest improvement was observed after 12-18 months of treatment with topical finasteride therapy. Topical finasteride 0.5% in combination with minoxidil 2% could represent a valid therapeutic option for the treatment of postmenopausal FPHL, showing higher efficacy than topical 17α-estradiol with minoxidil 2% both at 6-month and 12- to 18-month follow-up.
Sections du résumé
BACKGROUND AND OBJECTIVES
OBJECTIVE
Female pattern hair loss (FPHL) is a common form of scalp hair loss that occurs in 38% of females. Currently, minoxidil solution is the only therapy approved by the US Food and Drug Administration, but many other treatments are used, including cyproterone acetate, spironolactone, topical 17α-estradiol, and prostaglandin analogs. Systemic finasteride has been considered a treatment option in women even though its teratogenic effects tend to limit its prescription. Recently, topical finasteride has been evaluated to limit the side effect profile of the drug. The objective of the present study is to compare retrospectively the efficacy of topical 0.05% 17α-estradiol solution and a 0.5% finasteride lotion in the treatment of FPHL.
PATIENTS AND METHODS
METHODS
We enrolled 119 postmenopausal female patients. The first group comprised 69 women treated with finasteride 0.5% and minoxidil 2%. The second group included 50 women treated with 17α-estradiol 0.05% and minoxidil 2%. At baseline and at 6- and 12- to 18-month follow-up, global photographs were systematically taken. Three operators blind to the prescribed treatment evaluated photographs using a 7-point scale. One-way analysis of variance and unpaired Student t tests were performed to analyze 7-point scale scores.
RESULTS
RESULTS
The improvement was statistically significant from 6 months to 12-18 months, both for finasteride (P < 0.005) and 17α-estradiol (P < 0.05). The efficacy of topical finasteride was significantly greater than that of 17α-estradiol solution, both at the 6-month (P < 0.05) and at the 12- to 18-month follow-up (P < 0.005). In general, the highest improvement was observed after 12-18 months of treatment with topical finasteride therapy.
CONCLUSIONS
CONCLUSIONS
Topical finasteride 0.5% in combination with minoxidil 2% could represent a valid therapeutic option for the treatment of postmenopausal FPHL, showing higher efficacy than topical 17α-estradiol with minoxidil 2% both at 6-month and 12- to 18-month follow-up.
Identifiants
pubmed: 32363101
doi: 10.5826/dpc.1002a39
pii: dp1002a39
pmc: PMC7190559
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e2020039Informations de copyright
©2020 Rossi et al.
Déclaration de conflit d'intérêts
Competing interests: The authors have no conflicts of interest to disclose.
Références
Ann Dermatol. 2012 Aug;24(3):295-305
pubmed: 22879713
J Am Acad Dermatol. 2008 Oct;59(4):547-66; quiz 567-8
pubmed: 18793935
J Am Acad Dermatol. 1993 May;28(5 Pt 1):755-63
pubmed: 8496421
Ann Dermatol. 2017 Jun;29(3):276-282
pubmed: 28566902
Br J Dermatol. 2011 Dec;165 Suppl 3:2-6
pubmed: 22171678
J Drugs Dermatol. 2005 Sep-Oct;4(5):637-40
pubmed: 16167423
J Drugs Dermatol. 2018 Apr 1;17(4):457-463
pubmed: 29601622
Recent Pat Inflamm Allergy Drug Discov. 2012 May;6(2):130-6
pubmed: 22409453
J Invest Dermatol. 1992 Mar;98(3):315-9
pubmed: 1545141
Arch Dermatol. 1995 Dec;131(12):1373-5
pubmed: 7492124
Br J Dermatol. 2001 Feb;144(2):297-304
pubmed: 11251562
Dermatol Ther. 2016 Nov;29(6):424-432
pubmed: 27424565
Am J Clin Dermatol. 2019 Feb;20(1):147-153
pubmed: 30206824
J Investig Dermatol Symp Proc. 2003 Jun;8(1):24-7
pubmed: 12894991
Arch Dermatol. 2006 Mar;142(3):298-302
pubmed: 16549704
Int J Dermatol. 2019 Jul;58(7):759-776
pubmed: 30604525
Int J Womens Dermatol. 2018 Jun 19;4(4):203-211
pubmed: 30627618
Br J Dermatol. 2010 May;162(5):1135-7
pubmed: 20128792
J Investig Dermatol Symp Proc. 2005 Dec;10(3):217-21
pubmed: 16382668
Int J Clin Pharmacol Ther. 2014 Oct;52(10):842-9
pubmed: 25074865